Introduction
============

Oral cancer is the sixth most prevalent form of cancer [@B1]. Oral squamous cell carcinomas (OSCCs), comprising about 90% of all oral cancer [@B2], are the highest morbidity of all head and neck cancers [@B3]. More than 500,000 new cases and 300,000 deaths annually were reported [@B4]. Although great progress has been made for the treatment and diagnosis, the 5-year survival rates for patients with OSCCs remain unchanged at 50% to 55% from nearly 5 decades ago [@B5]. Therefore, understanding the molecular mechanisms underlying OSCC development and progression is necessary for improving the prognoses.

Synaptotagmins (SYTs) are membrane proteins comprised of a short N-terminal noncytoplasmic sequence, a single transmembrane region, a linker sequence of varying lengths, and two C2 domains. The SYTs were discovered because they are the Ca^2+^ sensor for neurotransmitter release in presynaptic nerve terminals, and SYT1 was identified first [@B6]. Eight of these SYTs have C2 domains that bind to Ca^2+^ (SYT1-3, 5-7, 9, and 10) while the other eight do not (Syt4, 8, and 11-16) [@B7]. The *SYT12* gene encodes a family of proteins involved in regulating transmitter release in the nervous system [@B8],[@B9].

A recent study reported that SYT12 overexpression was correlated with metastasis and SYT12 was a biomarker that tended to predict greater disease progression in patients with papillary thyroid cancer [@B10]. However, the molecular biologic role of SYT12 in cancer remains unknown. In the current study, we explain for the first time the novel molecular mechanism of SYT12 in OSCCs and evaluate a new candidate for medical treatment of OSCCs.

Materials and Methods
=====================

Ethics statement
----------------

The ethical committee of the Graduate School of Medicine, Chiba University, approved the research protocol (protocol number 680). All patients provided written informed consent before inclusion in the study.

Cells and tissue samples
------------------------

Eleven human OSCC-derived cell lines (HSC-2, HSC-3, HSC-3-M3, HSC-4, Sa3, Ca9-22, KOSC-2, SAS, SAS-H1, Ho-1-u-1, and Ho-1-N-1) were purchased from RIKEN BioResource Center (Tsukuba, Ibaraki, Japan) and the Japanese Collection of Research Bioresources Cell Bank (Ibaraki, Osaka, Japan) [@B11]-[@B13]. We obtained human normal oral keratinocyte (HNOKs) from young healthy patients and cultured the cells as described previously [@B14]-[@B17]. The cells used in this study were within 10 passages from thawing. They also were routinely tested using an EZ-PCR Mycoplasma Test Kit (Biological Industries, Kibbutz Beit Haemek, Israel).

mRNA expression analysis
------------------------

Total RNA was prepared using TRIZOL reagent (Invitrogen, Carlsbad, CA, USA). Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) was carried out as described previously [@B11],[@B18] with the following primers. The sequences of the gene-specific primers were as follows: *SYT12* (5′-CGAAGCCATGATCTTCTCG*-*3\' and 5\'-GCTCTCAGCCACCGTCAC-3\') and *glyceraldehyde-3-phosphate dehydrogenase* (*GAPDH*) (5′-AGCCACATCGCTCAGACAC-3′ and 5′-GCCCAATACGACCAAATCC-3′).

Reagents
--------

L-dopa was purchased from Cayman Chemical (Ann Arbor, MI, USA). The following antibodies were used: anti-SYT12 (M519) (Merck & Co., Inc., Kenilworth, NJ, USA); anti-CAMK2N1 (PA5-23740) (Invitrogen, CA, USA); anti-CAMK2 (ab52476) and anti-CAMK2 (Phospho T286) (ab32678) (abcam, Tokyo, Japan); anti-p27^Kip1^ (\#3686) and anti-CDK2 (\#2546) (Cell Signaling Technology, Danvers, MA, USA); anti-cyclin E (sc-377100), and GAPDH (sc-3223) (Santa Cruz Biotechnology, Santa Cruz, CA, USA).

Immunoblotting
--------------

Immunoblotting was performed as previously reported [@B15],[@B19] with each appropriate antibody mentioned previously.

Immunohistochemistry (IHC)
--------------------------

IHC and calculation of the IHC score were performed as described previously [@B15],[@B19]-[@B21], with appropriate antibody, anti-SYT12 (1:100 dilution), at 4°C. SYT12 was classified as positive and negative using the median score of all tumors as the cut-off points [@B22].

Transfection with shRNA plasmid
-------------------------------

We established stable knockdown transfectants, and the cell lines (HSC-3, SAS) were transfected with shRNA targeting (shSYT12) (sc-96796) and control shRNA (shMock) (sc-108060) (Santa Cruz Biotechnology, Santa Cruz, CA, USA) using Lipofectamine 3000 (Invitrogen, CA, USA) according to the manufacturer\'s protocol. The stable transfectants were isolated in a culture medium containing puromycin (2 µg/ml) (Santa Cruz Biotechnology, Santa Cruz, CA, USA). Four weeks after transfection, a small colony was viable. The cell colonies were picked, transferred to six-well plates, and expanded gradually to 10-cm dishes. To assess the efficiency of SYT12 knockdown, we performed RT-qPCR and immunoblotting.

Functional assays
-----------------

A proliferation assay, invasion assay, and migration assay were performed as described previously [@B22]-[@B30].

Cellular viability assay
------------------------

Cellular viability was measured using the MTS assay (Promega, Madison, WI, USA) [@B30]. MTS assays with cells (HSC-3, SAS) (5 × 10^3^) were performed in 96-well plates. After treatment with L-dopa (concentrations, 0, 50, 100, 200, 400, and 800 µM) for 24 h, we measured the 490-nm absorbance using a Benchmark Plus Microplate Reader (Bio-Rad, Hercules, CA, USA).

Cell cycle analysis
-------------------

Cell cycle analyses were performed as described previously [@B25],[@B27],[@B31]. shRNA transfected cells and L-dopa-treated cells were examined.

L-dopa treatment
----------------

To determine the appropriate concentration of L-dopa for OSCC cells, we performed the MTS assay, qRT-PCR, and immunoblotting. We then evaluate whether L-dopa affected the cellular proliferation and cell cycle. The cells were treated with L-dopa (50 µM) or dimethylsulfoxide as controls.

PCR array
---------

To identify genes that potentially interact with SYT12, we used qRT-PCR to analyze the Epithelial to Mesenchymal Transition RT^2^ Profiler PCR Array (Qiagen, Hilden, Germany).

Statistical analysis
--------------------

Each experiment was repeated at least three times, and all data are presented as the mean ± standard error of the mean. Statistical differences were analyzed using Fisher\'s exact test and a two-tailed, unpaired Student\'s *t*-test with Welch\'s correction for unequal variances using the BellCurve for Excel (Social Survey Research Information Co., Ltd.). P \< 0.05 was considered statistically significant.

Results
=======

Up-regulation of SYT12 in OSCC cell lines
-----------------------------------------

To investigate the status of the *SYT12* expression as a cancer-related gene, we first conducted qRT-PCR and immunoblot analysis with 11 OSCC-derived cell lines and HNOKs. *SYT12* mRNA expression was up-regulated significantly (P \< 0.05) in OSCC-derived cell lines other than Ho-1-U-1 compared with the HNOKs (Fig. [1](#F1){ref-type="fig"}A). Fig. [1](#F1){ref-type="fig"}B shows representative results of immunoblot analysis. The SYT12 protein level also increased in all OSCC cell lines compared with the HNOKs (Fig. [1](#F1){ref-type="fig"}B).

Evaluation of SYT12 status in primary OSCCs
-------------------------------------------

We evaluated the SYT12 expression in primary OSCCs by IHC and the IHC scoring system [@B22],[@B27],[@B31]. In oral normal tissues, the SYT12 IHC scores ranged from 8.1 to 134.2 (median, 43.0), while in OSCCs the scores ranged from 80.3 to 219.0 (median, 170.2). These IHC scores in primary OSCCs were significantly (P \< 0.05) higher than in normal oral tissues (Fig. [1](#F1){ref-type="fig"}C). Intense cytoplasmic and cell membrane staining was seen for SYT12, whereas the normal oral tissues showed negative staining. Representative IHC figures for SYT12 staining are shown (×200 magnification) (Fig. [1](#F1){ref-type="fig"}D). In the clinical classifications, SYT12-positive OSCCs (IHC scores \> median, 170.2) were associated significantly (P \< 0.05) with tumor size, regional lymph node metastasis, and the TNM stage of the OSCCs (Table [1](#T1){ref-type="table"}).

Establishment of stable SYT12 knockdown OSCC cells
--------------------------------------------------

HSC-3 and SAS were subjected to knockdown experiments because they had higher expression levels among the OSCC cell lines. We transfected shSYT12 and shMock vectors into the cells. To investigate the efficiency of the transfection, we performed qRT-PCR and immunoblot analysis. The SYT12 mRNA and protein expression levels in the shSYT12 cells decreased significantly (P \< 0.05) compared with the shMock cells (Fig. [2](#F2){ref-type="fig"}A, B).

Effect of shSYT12 cells on cellular growth and cell cycle
---------------------------------------------------------

To evaluate the effect of SYT12 knockdown on cellular growth, a cellular proliferation assay and cell cycle analyses were performed. We found a significant (P \< 0.05) decrease in cellular proliferation in the shSYT12 cells compared with the shMock cells (Fig. [2](#F2){ref-type="fig"}C). In the cell cycle analysis by flow cytometry, the percentage of the shSYT12 cells at the G1 phase was significantly (P \< 0.05) higher than that of the shMock cells (Fig. [2](#F2){ref-type="fig"}D). Analysis of the G1 phase-related protein by immunoblotting showed increased p27^Kip1^ and subsequent decreased expression of cyclin E and CDK2 and in the shSYT12 cells compared with the shMock cells (Fig. [2](#F2){ref-type="fig"}E).

Cellular migration and invasion assays
--------------------------------------

The migration assay showed that the area of micropipette wounds decreased significantly (P \< 0.05) in shSYT12 cells after 12 h compared with the shMock cells (Fig. [3](#F3){ref-type="fig"}A). Analysis of the invasion assay showed significantly lower (P \< 0.05) invasiveness of the shSYT12 cells compared with the shMock cells at 24 h (Fig. [3](#F3){ref-type="fig"}B).

Involvement of SYT12 signaling pathways that mediated the malignant phenotype of OSCCs
--------------------------------------------------------------------------------------

To obtain the data to support the involvement of SYT12 in cancer progression, we performed PCR arrays in the shMock and shSYT12 cells. CAMK2N1 had a significantly (P\<0.001) higher score (fold change, 12.4). CAMK2N1 is the endogenous inhibitor of CAMK2, which is activated by an increased intracellular Ca2+ concentration. CAMK2N1 expression was increased in the shSYT12 cells compared with the shMock cells. Furthermore, CAMK2 expression was similar in the shMock cells and shSYT12, but phosphorylation of CAMK2 decreased in the shSYT12 cells compared with the shMock cells (Fig. [3](#F3){ref-type="fig"}C).

L-dopa treatment
----------------

We detected the SYT12 inhibitor, L-dopa, using Ingenuity Pathway Analysis. To investigate the efficiency of L-dopa for OSCC cells (HSC-3, SAS), we performed an MTS assay, which showed significantly (P\<0.05) decreased cellular viability above L-dopa concentrations of 200 µM in a concentration-dependent manner (Fig. [4](#F4){ref-type="fig"}A). The inhibitory concentration 50s (IC~50~) for L-dopa in the HSC-3 and SAS cell lines were 259 nM and 196 nM, respectively. To verify the inhibitory effect of L-dopa on SYT12, the SYT12 expression was examined after treatment which various concentrations of L-dopa, by qRT-PCR and immunoblot analysis. L-dopa significantly (P\<0.05) inhibited the SYT12 mRNA and protein expression levels above concentrations of 50 µM in both cells compared with the control cells (Fig. [4](#F4){ref-type="fig"}B, C). Cellular growth of the L-dopa-treated cells were significantly (P \< 0.05) lower than the control cells at 144 h (Fig. [4](#F4){ref-type="fig"}D). Cell cycle analysis showed that the percentage of the L-dopa-treated cells at the G1 phase was significantly (P \< 0.05) higher than the control cells (Fig. [4](#F4){ref-type="fig"}E). The addition, L-dopa-treated cells showed that the p27^Kip1^ protein expression levels were up-regulated and the cyclin E and CDK2 levels were down-regulated compared with the control cells (Fig. [4](#F4){ref-type="fig"}F). These results indicated that L-dopa may regulate critical functions associated with tumoral growth through down-regulation of SYT12.

Discussion
==========

The current results showed that SYT12 knockdown was characterized by decreased cellular growth, invasiveness, and migratory activities with CAMK2N1 overexpression and decreased CAMK2-phospholyration. In addition, L-dopa, a drug for Parkinson\'s disease, controlled SYT12 expression, leading to similar phenotypes of SYT12 knockdown cells.

Previous studies have shown that the SYT family genes regulate proliferation, invasion, and metastasis in several cancer cells in addition to their roles in neuronal cells [@B32]-[@B35]. Of SYT family, SYT12 is detected as a biomarker of papillary thyroid cancer [@B10], but the molecular biologic function of SYT12 in other cancer cells and the interactions between SYT12 and cancer-associated signaling pathways remain unknown. To identify the SYT12-related genes, we conducted PCR array analysis using SYT12 knockdown cells and found that SYT12 affects the expression of CAMK2N1, inhibitor type1 of CAMK2, which is a known potent modulator of tumorigenesis [@B36]. CAMK2N1 expression has tumor-suppressing roles, such as depressed cell proliferation and cell cycle arrest in certain cancers [@B37]-[@B39]. Actually, SYT12 knockdown cells showed significant overexpression of CAMK2N1 (Fig. [3](#F3){ref-type="fig"}C), suggesting that down-regulation of SYT12 suppressed tumoral growth with cell cycle arrest by CAMK2N1 overexpression. CAMK2 is involved in controlling a range of cellular processes, including synaptic plasticity and memory consolidation [@B40],[@B41], vascular smooth muscle polarization [@B42], and cellular proliferation [@B43]. Moreover, several studies also suggest that CAMK2 regulates metastasis in several cancers [@B44]-[@B46]. The biologic properties of CAMK2 are controlled by multisite phosphorylations; when intracellular calcium levels rise, calcium binds to calmodulin, which activates CAMK2 and leads to self-phosphorylation of CAMK2 at T286 [@B47],[@B48]. Therefore, SYT12 may activate CAMK2 by decreased CAMK2N1 and increasing the intracellular calcium concentration in OSCCs, as a result, they promote the OSCC progression.

L-dopa is used widely to increase dopamine concentrations in the treatment of Parkinson\'s disease with a dopa decarboxylase inhibitor, such as carbidopa and benserazide, which inhibit aromatic amino acid decarboxylase, thus preventing the conversion of L-dopa into dopamine [@B49]. L-dopa was recently reported to suppress cellular growth via down-regulation of prolactin-mediated JAK2/STAT5A in breast cancer cells [@B50], and carbidopa was reported to be an aryl hydrocarbon receptor agonist and to suppress the growth of pancreatic cancer [@B51]. However, the role of L-dopa in oral cancer remains unknown. In the current study, we revealed for the first time that L-dopa led to down-regulation of SYT12 and decreased cellular proliferation by the cell cycle arrest at the G1 phase via p27^Kip1^.

In conclusion, we present here that SYT12 plays a significant role in OSCC progression via CAMK2N1 and CAMK2, and that L-dopa would be a new drug for OSCC treatment through the SYT12 expression.
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SYT12

:   Synaptotagmin12

OSCC

:   oral squamous cell carcinoma

L-dopa

:   L-3, 4-dihydroxyphenylalanine

HNOKS

:   human normal oral keratinocytes

CAMK2N1

:   calcium/calmodulin-dependent protein kinase 2 inhibitor 1

CAMK2

:   calcium/calmodulin-dependent protein kinase 2

![SYT12 expression in OSCC-derived cell lines and primary OSCCs. (A) Quantification of *SYT12* mRNA expression in OSCC-derived cell lines by qRT-PCR analysis (N=3). (B) Representative immunoblot analysis of SYT12 protein expression. The densitometric SYT12 protein data are normalized to GAPDH protein levels. The values are expressed as a percentage of the HNOKs (N=3). (C) The SYT12 IHC scores of the normal oral tissues and OSCCs (N=112). (D) Representative IHC results for SYT12 protein in normal tissue, primary OSCCs, and metastatic regional lymph nodes. Original magnification, x200. Scale bars, 50 μm.](jcav10p4913g001){#F1}

![Establishment of SYT12 knockdown cells and decreased cell growth via cell cycle arrest at G1 phase. (A, B) Expression of SYT12 mRNA and protein in shMock and shSYT12 cells (HSC-3 and SAS-derived transfectants) (N=3). (C) The cellular growth of the shSYT12 cells are decreased significantly (P \< 0.05) compared with the shMock cells after 7 days (168 h) (N=3). (D) A flow cytometric analysis shows that the percentage of the shSYT12 cells in the G1 phase is increased compared with the shMock cells (N=3). (E) Immunoblotting analysis shows up-regulation of p27^Kip1^ and down-regulation of cyclin E and CDK2 in the shSYT12 cells compared with the shMock cells (N=3).](jcav10p4913g002){#F2}

![Involvement of the SYT12 signaling pathways that mediate the migratory and invasiveness phenotype of OSCCs. (A) Migration assay of shMock cells and shSYT12 cells (N=3). (B) Invasion assay of shMock cells and shSYT12 cells at 24h (N=3). (C) Immunoblot analysis shows CAMK2N1 expression is increased in the shSYT12 cells, CAMK2 expression is similar in the shMock cells and shSYT12, but phosphorylation of CAMK2 (p-CAMK2) is decreased in the shSYT12 cells compared with the shMock cells (N=3).](jcav10p4913g003){#F3}

![L-dopa treatment. (A) An MTS assay shows a significant decrease in cellular viability above L-dopa concentrations of 200 µM in a concentration-dependent manner (N=3). (B, C) L-dopa concentrations above 50 µM inhibit SYT12 mRNA and protein expression levels in the L-dopa-treated cells compared with controls (N=3). (D) The cellular growth of the L-dopa-treated cells is significantly (P \< 0.05) lower than that of the control cells after 7 days (168 h) (N=3). (E) A flow cytometric analysis shows the percentage of L-dopa-treated cells in the G1 phase is increased compared with the control cells (N=3). (F) Immunoblot analysis shows up-regulation of p27^Kip1^ and down-regulation of CDK2 and cyclin E in the L-dopa-treated cells compared with the control cells (N=3).](jcav10p4913g004){#F4}

###### 

Correlation between SYT12 expression and clinical classification in OSCCs.

  ---------------------------------------------------------------------------
  Clinical classification        Results of immunostaining\        
                                 No. patients                      
  ------------------------- ---- ---------------------------- ---- ----------
  Age at surgery (years)                                           

  \< 60                     26   12                           14   0.823

  ≧60                       86   44                           42   

                                                                   

                                                                   

  Gender                                                           

  Male                      66   32                           34   0.706

  Female                    46   24                           22   

                                                                   

  T-primary tumor                                                  

  T1+T2                     64   38                           26   0.035^‡^

  T3+T4                     48   18                           30   

                                                                   

  N-regional lymph node                                            

  Negative                  74   43                           31   0.028^‡^

  Positive                  38   13                           25   

                                                                   

  TNM Stage                                                        

  I+II                      46   30                           16   0.012^‡^

  III+IV                    66   26                           40   

                                                                   

                                                                   

  Vascular invasion                                                

  Negative                  88   48                           40   0.106

  Positive                  24   8                            16   

                                                                   

  Histopathologic type                                             

  Well                      86   45                           41   0.503

  Moderately+Poorly         26   11                           15   

                                                                   
  ---------------------------------------------------------------------------

Fisher\'s exact test, ^‡^*P* \< 0.05.
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